Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus

Annals of the Rheumatic Diseases

Volumn 68, Issue 1, 2009, Pages 110-116

  Stummvoll, G H ^a   Fritsch, R D ^b   Meyer, B ^a   Hoefler, E ^c   Aringer, M ^a   Smolen, J S ^a,c,d   Steiner, G ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Hietzing Hospital   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; GAMMA INTERFERON; HISTONE ANTIBODY; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; THYMIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INFLAMMATORY INFILTRATE; LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH1 CELL;

AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONES; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LUPUS ERYTHEMATOSUS, SYSTEMIC; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58349094934     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.082032     Document Type: Article

References (52)

1. Ebling FM, Hahn BH. Pathogenic subsets of antibodies to DNA. Int Rev Immunol 1989; 5:79-95.
2. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993; 91:1687-96.
3. Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M, Lorenz HM, et al. Histonespecific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997; 40:2162-71.
4. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94:184-92.
5. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992; 90:165-73.
6. Rubin RL, Burlingame RW, Arnott JE, Totoritis MC, McNally EM, Johnson AD. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamideinduced lupus. J Immunol 1995; 154:2483-93.
7. Konikoff F, Swissa M, Shoenfeld Y. Autoantibodies to histones and their subfractions in chronic liver diseases. Clin Immunol Immunopathol 1989; 51:77-82.
8. Costa 0, Monier JC. Antihistone antibodies detected by ELISA and immunoblotting in systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 1986; 13:722-5.
9. Garzelli C, Incaprera M, Bazzichi A, Manunta M, Rognini F, Falcone G. Epstein-Barr virus-transformed human B lymphocytes produce natural antibodies to histones. Immunol Lett 1994; 39:277-82.
10. Schett G, Smolen J, Zimmermann C, Hiesberger H, Hoefler E, Fournel S, et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 2002; 11:704-15.
11. Shoenfeld Y, Segol O. Anti-histone antibodies in SLE and other autoimmune diseases. Clin Exp Rheumatol 1989; 7:265-71.
12. Gioud M, Kaci MA, Monier JC. Histone antibodies in systemic lupus erythematosus. A possible diagnostic tool. Arthritis Rheum 1982; 25:407-13.
13. Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000; 43:420-8.
14. Hochberg NIC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
15. Schett G, Steiner G, Smolen JS. Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation. Arthritis Rheum 1998; 41:1446-55.
16. van Es JH, Gmelig Meyling FH, van de Akker WR, Aanstoot H, Derksen RH, Logtenberg T. Somatic mutations in the variable regions of a human IgG anti-doublestranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. J Exp Med 1991; 173:461-70.
17. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992; 22:1719-28.
18. Kasaian NIT, Ikematsu H, Balow JE, Casali P. Structure of the VH and VL segments of monoreactive and polyreactive IgA autoantibodies to DNA in patients with systemic lupus erythematosus. J Immunol 1994; 152:3137-51.
19. Kaliyaperumal A, Michaels MA, Datta SK. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. J Immunol 2002; 168:2530-7.
20. Rajagopalan S, Mao C, Datta SK. Pathogenic autoantibody-inducing γ/δ T helper cells from patients with lupus nephritis express unusual T cell receptors. Clin Immunol Immunopathol 1992; 62:344-50.
21. Schitfenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 2004; 50:2415-22.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
23. Vitali C, Bencivelli W, Mosca M, Carrai P, Sereni M, Bombardieri S. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 1999; 26:498-501.
24. Smolen JS. Clinical and serologic features: incidence and diagnostic approach. In: Smolen JS, Zielinski CC, eds. Systemic lupus erythematosus. Berlin, Germany: Springer Verlag, 1987:171-96.
25. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10:549-54.
26. Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, et al. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 2002; 169:1068-76.
27. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116:213-19.
28. Scheinecker C, Machold KP, Majdic O, Hocker P, Knapp W, Smolen JS. Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol 1998; 161:3966-73.
29. Fritsch-Stork R, Mullegger D, Skriner K, Jahn-Schmid B, Smolen JS, Steiner G. The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus. Arthritis Res Ther 2006; 8:R118.
30. Fritsch R, Bohle B, Vollmann U, Wiedermann U, Jahn-Schmid B, Krebitz M, et al. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998; 102:679-86.
31. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88:346-50.
32. Hassfeld W, Steiner G, Studnicka-Benke A, Skriner K, Graninger W, Fischer I, et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995; 38:777-85.
33. Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW. Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum 2004; 50:2216-22.
34. Monneaux F, Muller S. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins. Scand J Immunol 2001; 54:45-54.
35. Suen JL, Chuang YH, Tsai BY, Yau PM, Chiang BL. Treatment of murine lupus using nucleosomal T cell epitopes identified by bone marrow-derived dendritic cells. Arthritis Rheum 2004; 50:3250-9.
36. Kaliyaperumal A, Michaels MA, Datta SK. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 1999; 162:5775-83.
37. Datta SK. Major peptide autoepitopes for nucleosome-centered T and B cell interaction in human and murine lupus. Ann NY Acad Sci 2003; 987:79-90.
38. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996; 183:2459-69.
39. Gebhard KL, Veldman CM, Wassmuth R, Schultz E, Schuler G, Hertl M. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp Dermatol 2005; 14:586-92.
40. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346:183-7.
41. Hoffman RW, Takeda Y, Sharp GC, Lee DR, Hill DL, Kaneoka H, et al. Human T cell clones reactive against U-small nuclear ribonucleoprotein autoantigens from connective tissue disease patients and healthy individuals. J Immunol 1993; 151:6460-9.
42. Mudd PA, Teague BN, Farris AD. Regulatory T cells and systemic lupusb erythematosus. Scand J Immunol 2006; 64:211-18.
43. Wucherpfennig KW, Zhang J, Witek C, Matsui M, Modabber Y, Ota K, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994; 152:5581-92.
44. Oliveira EM, Bar-Or A, Waliszewska Al, Cai G, Anderson DE, Krieger Jl, et al. A. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J Autoimmun 2003; 20:71-81.
45. Housslau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4:393-5.
46. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, lL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
47. Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 1999; 42:1644-8.
48. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44:2097-106.
49. Takahashi S, Fossati L, Iwamoto M, Merino R, Motta R, Kobayakawa T, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest 1996; 97:1597-604.
50. Khalil M, Inaba K, Steinman R, Ravetch J, Diamond B. T cell studies in a peptideinduced model of systemic lupus erythematosus. J Immunol 2001; 166:1667-74.
51. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11:102-8.
52. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50:3161-9.